Cargando…
To screen or not to screen? Celiac antibodies in liver diseases
Celiac disease (CD) is a systemic immune-mediated disorder triggered by dietary gluten in genetically predisposed individuals. The typical symptoms are anemia, diarrhea, fatigue, weight loss, and abdominal pain. CD has been reported in patients with primary sclerosing cholangitis, primary biliary ch...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5296194/ https://www.ncbi.nlm.nih.gov/pubmed/28223722 http://dx.doi.org/10.3748/wjg.v23.i5.776 |
_version_ | 1782505566912905216 |
---|---|
author | Narciso-Schiavon, Janaína Luz Schiavon, Leonardo Lucca |
author_facet | Narciso-Schiavon, Janaína Luz Schiavon, Leonardo Lucca |
author_sort | Narciso-Schiavon, Janaína Luz |
collection | PubMed |
description | Celiac disease (CD) is a systemic immune-mediated disorder triggered by dietary gluten in genetically predisposed individuals. The typical symptoms are anemia, diarrhea, fatigue, weight loss, and abdominal pain. CD has been reported in patients with primary sclerosing cholangitis, primary biliary cholangitis, autoimmune hepatitis, aminotransferase elevations, nonalcoholic fatty liver disease, hepatitis B, hepatitis C, portal hypertension and liver cirrhosis. We evaluate recommendations for active screening for CD in patients with liver diseases, and the effect of a gluten-free diet in these different settings. Active screening for CD is recommended in patients with liver diseases, particularly in those with autoimmune disorders, steatosis in the absence of metabolic syndrome, noncirrhotic intrahepatic portal hypertension, cryptogenic cirrhosis, and in the context of liver transplantation. In hepatitis C, diagnosis of CD can be important as a relative contraindication to interferon use. Gluten-free diet ameliorates the symptoms associated with CD; however, the associated liver disease may improve, remain the same, or progress. |
format | Online Article Text |
id | pubmed-5296194 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-52961942017-02-21 To screen or not to screen? Celiac antibodies in liver diseases Narciso-Schiavon, Janaína Luz Schiavon, Leonardo Lucca World J Gastroenterol Review Celiac disease (CD) is a systemic immune-mediated disorder triggered by dietary gluten in genetically predisposed individuals. The typical symptoms are anemia, diarrhea, fatigue, weight loss, and abdominal pain. CD has been reported in patients with primary sclerosing cholangitis, primary biliary cholangitis, autoimmune hepatitis, aminotransferase elevations, nonalcoholic fatty liver disease, hepatitis B, hepatitis C, portal hypertension and liver cirrhosis. We evaluate recommendations for active screening for CD in patients with liver diseases, and the effect of a gluten-free diet in these different settings. Active screening for CD is recommended in patients with liver diseases, particularly in those with autoimmune disorders, steatosis in the absence of metabolic syndrome, noncirrhotic intrahepatic portal hypertension, cryptogenic cirrhosis, and in the context of liver transplantation. In hepatitis C, diagnosis of CD can be important as a relative contraindication to interferon use. Gluten-free diet ameliorates the symptoms associated with CD; however, the associated liver disease may improve, remain the same, or progress. Baishideng Publishing Group Inc 2017-02-07 2017-02-07 /pmc/articles/PMC5296194/ /pubmed/28223722 http://dx.doi.org/10.3748/wjg.v23.i5.776 Text en ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Review Narciso-Schiavon, Janaína Luz Schiavon, Leonardo Lucca To screen or not to screen? Celiac antibodies in liver diseases |
title | To screen or not to screen? Celiac antibodies in liver diseases |
title_full | To screen or not to screen? Celiac antibodies in liver diseases |
title_fullStr | To screen or not to screen? Celiac antibodies in liver diseases |
title_full_unstemmed | To screen or not to screen? Celiac antibodies in liver diseases |
title_short | To screen or not to screen? Celiac antibodies in liver diseases |
title_sort | to screen or not to screen? celiac antibodies in liver diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5296194/ https://www.ncbi.nlm.nih.gov/pubmed/28223722 http://dx.doi.org/10.3748/wjg.v23.i5.776 |
work_keys_str_mv | AT narcisoschiavonjanainaluz toscreenornottoscreenceliacantibodiesinliverdiseases AT schiavonleonardolucca toscreenornottoscreenceliacantibodiesinliverdiseases |